No quarterly revenue total was found in ATOSSA THERAPEUTICS, INC.'s SEC filings.
Atossa Therapeutics, Inc. (ATOS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$9.6 million.
Revenue
—
Net income
$-8.49M
-0.8% vs year-ago quarter
Operating cash flow
$-9.64M
-32.9% vs year-ago quarter
Free cash flow
$-9.64M
-32.9% vs year-ago quarter
EPS
$-0.95
+3.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.98M
-92.3% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1488039
- Former names
- ATOSSA GENETICS INC (until Nov 13, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$8.7M | -$9.9M | -$11.4M | -$9.3M | -$9.0M |
| Net income | -$8.5M | -$9.6M | -$10.9M | -$8.7M | -$8.4M |
| Diluted EPS | -$0.95 | -$1.11 | $0.03 | -$0.07 | -$0.98 |
| Operating cash flow | -$9.6M | -$9.6M | -$10.5M | -$6.0M | -$7.3M |
| Free cash flow | -$9.6M | -$9.6M | -$10.5M | -$6.0M | -$7.3M |
| Total assets | $32.3M | $37.9M | $47.6M | $58.0M | $64.5M |
| Total liabilities | $5.5M | $7.5M | $8.3M | $8.2M | $6.8M |
| Stockholders' equity | $26.8M | $30.5M | $39.4M | $49.8M | $57.7M |
| Cash and investments | $26.1M | $31.7M | $41.3M | $51.8M | $57.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights, Other events
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 11, 2026 | Jun 10, 2026 |
All 641 Atossa Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.